Pipeline

Our internally developed pipeline of next-generation tyrosine kinase inhibitors (TKIs) target genetic drivers of cancer in both TKI-naïve and TKI-pretreated patients. We hold development and commercialization rights to our drug candidates in all regions expect repotrectinib in certain countries in Greater China.